BTIG Cuts Keryx Biopharmaceuticals (KERX) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results
August 5, 2015 7:01 AM EDTMajority of phosphate binder patients today have access to Auryxia
CHMP recently adopted a positive opinion for Fexeric® (ferric citrate coordination complex) in the EU
Enrollment complete in ongoing Phase 3 label-expansion study for Auryxia
BOSTON, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced its financial results for the second quarter ended June 30, 2015.
"We are making progress on several important milestones across our... More
